Merck (MRK) Asset Writedowns and Impairment (2010 - 2023)

Merck (MRK) has 14 years of Asset Writedowns and Impairment data on file, last reported at $779.0 million in Q4 2023.

• Asset Writedowns and Impairment for Q4 2023 came in at $779.0 million, down 7.15% year-over-year; the trailing twelve-month figure through Dec 2023 was $2.8 billion (up 38.41% YoY), and the FY2025 annual result was $55.0 million, up 41.03% from the prior year.
• Asset Writedowns and Impairment fell to $779.0 million in Q4 2023 per MRK's latest filing, from $839.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $1.7 billion in Q4 2020 and troughed at $15.0 million in Q3 2020.
• A 5-year average of $505.9 million and a median of $302.0 million in 2021 frame the typical range for Asset Writedowns and Impairment.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 856.25% in 2020 and fell as far as 97.55% in 2020.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $176.0 million in 2019, then surged by 856.25% to $1.7 billion in 2020, then plunged by 82.06% to $302.0 million in 2021, then soared by 177.81% to $839.0 million in 2022, then decreased by 7.15% to $779.0 million in 2023.
• Business Quant data shows MRK's Asset Writedowns and Impairment at $779.0 million in Q4 2023, $839.0 million in Q4 2022, and $887.0 million in Q3 2022.